TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29728717

Group type: EXPERIMENTAL
Intervention: Phenylalanine
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: Histidine
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: Tyrosine
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: Alanine
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: Leucine
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: Valine
Number of subjects: 3587

Group type: EXPERIMENTAL
Intervention: All amino acids
Number of subjects: 3587
Study: 29728755

Group type: EXPERIMENTAL
Intervention: Remifentanil (2.68-3.11 µg/kg) co-administered with propofol (3 mg/kg)
Number of subjects: 27
Study: 29728798

Group type: EXPERIMENTAL
Intervention: Irinotecan-based chemotherapy
Number of subjects: 164
Study: 29729048

Group type: EXPERIMENTAL
Intervention: Prospective period
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in Northern Europe/Canada
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in Eastern Europe
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in South East Asia
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in South East Asia
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in Eastern Europe
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in Russia
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in Russia
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes in Latin America
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in Latin America
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes in Northern Europe/Canada
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Blood glucose cut-off for Type 1 diabetes
Number of subjects: 27585

Group type: EXPERIMENTAL
Intervention: Blood glucose cut-off for Type 2 diabetes
Number of subjects: 27585
Study: 29729809

Group type: EXPERIMENTAL
Intervention: Treat and Extend Ranibizumab
Number of subjects: 0
Study: 29730244

Group type: EXPERIMENTAL
Intervention: Barriers related to marginalization
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Overall BCQ score
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Caregivers reporting barriers related to expectations, knowledge, pragmatics, and skills
Number of subjects: 395
Study: 29730377

Group type: EXPERIMENTAL
Intervention: Dexamethasone delivery adjunctive to standard endovascular revascularization
Number of subjects: 262
Study: 29730602

Group type: EXPERIMENTAL
Intervention: Deep learning Radiomics of elastography (DLRE)
Number of subjects: 398

Group type: COMPARATOR
Intervention: 2D-SWE
Number of subjects: 398

Group type: COMPARATOR
Intervention: Aspartate transaminase-to-platelet ratio index
Number of subjects: 398

Group type: COMPARATOR
Intervention: Fibrosis index based on four factors
Number of subjects: 398
Study: 29730603

Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 38

Group type: COMPARATOR
Intervention: Infliximab (control)
Number of subjects: 38
Study: 29730613

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 135
Study: 29730615

Group type: EXPERIMENTAL
Intervention: High-dose medical exercise therapy (MET) - 70-90 minutes per session, 3 times a week for 12 weeks (total of 36 sessions)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-dose medical exercise therapy (MET) - 20-30 minutes per session, 3 times a week for 12 weeks (total of 36 sessions)
Number of subjects: 200
Study: 29730632

Group type: EXPERIMENTAL
Intervention: Questionnaire on urinary function
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Questionnaire on bowel function
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Questionnaire on sexual function
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 3000
Study: 29730646

Group type: EXPERIMENTAL
Intervention: Phospholipid biomarker panel (10 phospholipid species)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: CAD patients with significant depressive symptoms
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (CAD patients without significant depressive symptoms)
Number of subjects: 86
Study: 29730991

Group type: EXPERIMENTAL
Intervention: Paced hyperventilation followed by breath-hold during oxygenation-sensitive CMR (OS-CMR) imaging.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Breath-hold maneuver during OS-CMR imaging.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group of ten healthy subjects undergoing the same CMR protocol.
Number of subjects: 26
Study: 29731369

Group type: EXPERIMENTAL
Intervention: Tailored frequency-escalated primary prophylaxis with standard half-life recombinant factor VIII (SHL-rFVIII), starting at 50 IU/kg once weekly, escalating in frequency and dosage as needed.
Number of subjects: 56
Study: 29731615

Group type: EXPERIMENTAL
Intervention: Elderly Activity Performance Intervention (n=144)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Usual practice (n=231)
Number of subjects: 375
Study: 29731779

Group type: EXPERIMENTAL
Intervention: NSC-mediated therapy
Number of subjects: 12
Study: 29731919

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy (docetaxel, cisplatin, and 5-fluorouracil)
Number of subjects: 256
Study: 29732957

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Blinded pCLE reinterpretation
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: In vivo pCLE interpretation
Number of subjects: 21
Study: 29733493

Group type: EXPERIMENTAL
Intervention: RIETE score
Number of subjects: 687

Group type: COMPARATOR
Intervention: PESI
Number of subjects: 687

Group type: COMPARATOR
Intervention: sPESI
Number of subjects: 687

Group type: COMPARATOR
Intervention: GPS
Number of subjects: 687

Group type: COMPARATOR
Intervention: All scores
Number of subjects: 687
Study: 29733524

Group type: EXPERIMENTAL
Intervention: Veliparib extended-release (ER) 800 mg once daily or 600 mg twice daily
Number of subjects: 71

Group type: COMPARATOR
Intervention: Veliparib extended-release (ER) 200 mg (fasting)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Veliparib extended-release (ER)
Number of subjects: 71
Study: 29733771

Group type: EXPERIMENTAL
Intervention: Birabresib 80 mg once daily (cohort A)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Birabresib 100 mg for 7 consecutive days (cohort B)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Birabresib (80 mg once daily)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Birabresib (80 mg once daily) in patients with NMC
Number of subjects: 46
Study: 29734398

Group type: EXPERIMENTAL
Intervention: OSA50
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: DES-OSA
Number of subjects: 159

Group type: COMPARATOR
Intervention: STOP-Bang
Number of subjects: 159

Group type: COMPARATOR
Intervention: P-SAP
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 159
Study: 29734865

Group type: EXPERIMENTAL
Intervention: Participants with PAD (ABI < 0.90)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Participants without PAD
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Lower ABI values
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Mitochondrial DNA copy number
Number of subjects: 44
Study: 29734948

Group type: EXPERIMENTAL
Intervention: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 800 μg twice daily for 1 week
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 200 μg twice daily for 1 week
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 400 μg twice daily for 1 week
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP) at 600 μg twice daily for 1 week
Number of subjects: 41
Study: 29734953

Group type: EXPERIMENTAL
Intervention: Amisulpride (dopamine D2/3 receptor antagonist) treatment for 6 weeks
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 56
Study: 29734966

Group type: EXPERIMENTAL
Intervention: Nutrient intake in 2010 for rural participants (men 9.7 MJ/d; women 9.1 MJ/d)
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Increased percentage of energy from animal protein, total fat, saturated fat (not urban women), monounsaturated fat, and added sugar
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Higher energy intake in 2010
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Shift towards higher energy intakes and an animal food-based diet
Number of subjects: 2000
Study: 29734990

Group type: EXPERIMENTAL
Intervention: PAP therapy for 6 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Exosomes isolated before PAP therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Exosomes isolated after PAP therapy
Number of subjects: 12
Study: 29735299

Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitor (TKI) therapy discontinuation
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Imatinib as first-line treatment
Number of subjects: 755
Study: 29735476

Group type: EXPERIMENTAL
Intervention: Rebound exercise
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Circuit training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study: 29735511

Group type: EXPERIMENTAL
Intervention: T1-weighted muscle MRI
Number of subjects: 182
Study: 29735608

Group type: EXPERIMENTAL
Intervention: Modified two-stage model incorporating a questionnaire and oximetry
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Original two-stage model
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Modified questionnaire
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3% oxygen desaturation index
Number of subjects: 100
Study: 29735994

Group type: EXPERIMENTAL
Intervention: Toca 511 (retroviral replicating vector) followed by 5-fluorocytosine (5-FC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toca 511 (retroviral replicating vector)
Number of subjects: 0
Study: 29736158

Group type: EXPERIMENTAL
Intervention: IVIg-SN 10%
Number of subjects: 81
Study: 29736243

Group type: EXPERIMENTAL
Intervention: AL-335, odalasvir, and simeprevir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29736467

Group type: EXPERIMENTAL
Intervention: Monolithic zirconia dental prostheses
Number of subjects: 101
Study: 29736468

Group type: EXPERIMENTAL
Intervention: Vena cava ultrasound for volemic status assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive legs raising test for volemic status assessment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard method (empirical fluid administration)
Number of subjects: 0
Study: 29736474

Group type: EXPERIMENTAL
Intervention: Standardized laparoscopic intraperitoneal onlay mesh repair (IPOM) for incisional hernia
Number of subjects: 0
Study: 29736473

Group type: EXPERIMENTAL
Intervention: 4 cups of instant regular coffee daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: 4 cups of a coffee-like placebo beverage daily
Number of subjects: 128
Study: 29736475

Group type: EXPERIMENTAL
Intervention: Improved cookstoves and household water filters
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100000
Study: 29736482

Group type: EXPERIMENTAL
Intervention: In-person prehabilitation (n=12) - 12-week rehabilitation program (2 sessions/week) including education, exercises of the lower limb and cardiovascular training.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Tele-prehabilitation (n=12) - same intervention as in-person using telecommunication software.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n=12) - provided with the hospital's usual documentation before surgery.
Number of subjects: 36
Study: 29737243

Group type: EXPERIMENTAL
Intervention: Subcutaneous administration of paracetamol
Number of subjects: 160
Study: 29738425

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine (50-100 mg/day)
Number of subjects: 18
Study: 29738929

Group type: EXPERIMENTAL
Intervention: Symptomatic group (musicians with prolonged PRMSDs)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (musicians without prolonged PRMSDs)
Number of subjects: 72
Study: 29739353

Group type: EXPERIMENTAL
Intervention: Serum prolactin level measured 2 hours after OPU
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Serum prolactin levels before OPU
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clinical pregnancy rates
Number of subjects: 90
Study: 29739356

Group type: EXPERIMENTAL
Intervention: 3 cycles of consolidation chemotherapy before TME, followed by 5 cycles of adjuvant chemotherapy (experimental arm)
Number of subjects: 358

Group type: COMPARATOR
Intervention: 8 cycles of adjuvant chemotherapy (control arm)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 358
Study: 29739389

Group type: EXPERIMENTAL
Intervention: Higher-protein group (median protein intake 4.3 g/kg/d)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lower-protein group (median protein intake 3.7 g/kg/d)
Number of subjects: 60
Study: 29739393

Group type: EXPERIMENTAL
Intervention: Nursing home treatment for dehydration or bacterial infections
Number of subjects: 299

Group type: COMPARATOR
Intervention: Hospital treatment for dehydration or bacterial infections
Number of subjects: 299
Study: 29739430

Group type: EXPERIMENTAL
Intervention: Low PEEP (0 to 5 cm H2O)
Number of subjects: 980

Group type: COMPARATOR
Intervention: High PEEP (not specified)
Number of subjects: 980
Study: 29739447

Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Total body water at week 36
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Gestational weight gain (GWG) increase
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Fat mass in week 36
Number of subjects: 550
Study: 29739754

Group type: EXPERIMENTAL
Intervention: Dexpramipexole (150 mg orally twice daily)
Number of subjects: 10
Study: 29739786

Group type: EXPERIMENTAL
Intervention: mHealth technology with CHW home visit on postoperative day 10 (±3 days) for SSI screening
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: mHealth technology with CHW phone screening for SSI
Number of subjects: 100

Group type: COMPARATOR
Intervention: No follow-up care (control group)
Number of subjects: 100
Study: 29739796

Group type: EXPERIMENTAL
Intervention: Carotid ultrasound assessment of atherosclerotic carotid plaques and carotid intima-media thickness (cIMT)
Number of subjects: 3683

Group type: EXPERIMENTAL
Intervention: Carotid ultrasound assessment of cIMT
Number of subjects: 3683
Study: 29739917

Group type: EXPERIMENTAL
Intervention: General Anesthesia
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conscious Sedation
Number of subjects: 128
Study: 29740358

Group type: EXPERIMENTAL
Intervention: Psychotherapy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline amygdala-frontoparietal connectivity
Number of subjects: 0
Study: 29740629

Group type: EXPERIMENTAL
Intervention: Meat harvested with lead bullets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 29740638

Group type: EXPERIMENTAL
Intervention: Mediterranean-based dietary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 0
Study: 29740637

Group type: EXPERIMENTAL
Intervention: PROTECT preventive intervention group (cognitive-behavioral 4-session brief-protocol)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Assessment only control group
Number of subjects: 340
Study: 29740641

Group type: EXPERIMENTAL
Intervention: Progressive resistance training with elastic bands for 3 weeks followed by home-based progressive resistance training for 9 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation including general physical exercise for 3 weeks followed by home-based general physical exercise for 9 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Progressive resistance training with elastic bands
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multidisciplinary rehabilitation including general physical exercise
Number of subjects: 100
Study: 29740788

Group type: COMPARATOR
Intervention: Provider education on guidelines for the appropriate treatment of ARIs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Suggested Alternatives (computerized clinical decision support)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accountable Justification (free-text justification in electronic health record)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer Comparison (periodic email about inappropriate prescribing rates)
Number of subjects: 0
Study: 29741239

Group type: EXPERIMENTAL
Intervention: Floss-brush group
Number of subjects: 25

Group type: COMPARATOR
Intervention: Brush-floss group
Number of subjects: 25
Study: 29741279

Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation strategies introduced at cancer diagnosis
Number of subjects: 75
Study: 29741298

Group type: EXPERIMENTAL
Intervention: VEGF-A increase > 45% on day 5
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: VEGF-A increase < 45% on day 5
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: VEGF-A levels in mouse BAL and lung tissue
Number of subjects: 82

Group type: COMPARATOR
Intervention: Bevacizumab pre-treatment in mice
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: VEGF-A levels in patients
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: APACHE II and SOFA scores
Number of subjects: 82
Study: 29741409

Group type: EXPERIMENTAL
Intervention: ixazomib-Rd (n=360)
Number of subjects: 722

Group type: COMPARATOR
Intervention: placebo-Rd (n=362)
Number of subjects: 722
Study: 29741697

Group type: COMPARATOR
Intervention: l-lysine (10, 13, 16, and 18 mg · kg-1 · d-1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: l-tryptophan (0.5, 1, 1.5, and 2 mg · kg-1 · d-1)
Number of subjects: 13
Study: 29742009

Group type: EXPERIMENTAL
Intervention: Neoadjuvant dose-dense gemcitabine and cisplatin (ddGC)
Number of subjects: 0
Study: 29742471

Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT) received ≤ 48 h post-initiation, mean duration 8.8 days, 62.5% received monotherapy.
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: Initial antibiotic therapy (IAT)
Number of subjects: 451
Study: 29742672

Group type: EXPERIMENTAL
Intervention: More than 1 day of bleeding
Number of subjects: 2307

Group type: COMPARATOR
Intervention: No bleeding
Number of subjects: 2307

Group type: COMPARATOR
Intervention: 1 day of bleeding
Number of subjects: 2307
Study: 29743027

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging at 1h
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging at 3h
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Comparison of SUVmean to cSUVmean
Number of subjects: 102
Study: 29743043

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX)
Number of subjects: 58
Study: 29743045

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 167

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 167
Study: 29743094

Group type: EXPERIMENTAL
Intervention: Low-flow extracorporeal carbon-dioxide removal (ECCO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-flow ECCO
Number of subjects: 20
Study: 29743148

Group type: EXPERIMENTAL
Intervention: Secondary cytoreductive surgery followed by platinum-based chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 29743156

Group type: EXPERIMENTAL
Intervention: CareSage risk assessment system with nurse triage calls and personalized interventions
Number of subjects: 370
Study: 29743226

Group type: EXPERIMENTAL
Intervention: 5As Team intervention
Number of subjects: 29
Study: 29743836

Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg BID
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg BID
Number of subjects: 121

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 121
Study: 29744054

Group type: EXPERIMENTAL
Intervention: Relaxing audio
Number of subjects: 38

Group type: COMPARATOR
Intervention: Neutral stimulus (control)
Number of subjects: 38
Study: 29744332

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29745457

Group type: EXPERIMENTAL
Intervention: Darunavir
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Atazanavir
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Pooled population
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Baseline Framingham score
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: AIx@75
Number of subjects: 33
Study: 29745476

Group type: EXPERIMENTAL
Intervention: Culprit plaque rupture (CPR)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Necrotic core with macrophage infiltrations (NCMI)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Dual antiplatelet therapy with prasugrel/ticagrelor at discharge
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Follow-up duration
Number of subjects: 209
Study: 29746485

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: NNRTI/PI-based ART
Number of subjects: 100
Study: 29746631

Group type: EXPERIMENTAL
Intervention: Medically attended influenza (CFRMA) during the pandemic period (2009-2011)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Hospitalization rate of pH1N1-positive outpatients
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Mortality rate of pH1N1-positive inpatients
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: CFRAR for the 2009 pandemic
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: CFRMA for young adults during the post-pandemic period
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: CFR for influenza-negative patients
Number of subjects: 843